Enlivex Ltd (ENLV) Stock AnalysisENLVEnlivex Ltd

Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Enlivex Therapeutics is not a good buy right now due to its current price of $1.41, which is significantly below its 52-week high of $434.40. The stock has experienced a staggering year-to-date change of -99.22%, indicating severe underperformance. Additionally, the RSI is at a very low 7.231, suggesting the stock is oversold, but this may not be enough to justify a buy given the risks involved. The main risk is the upcoming earnings report on November 13, 2026, where the EPS estimate is -4.48, indicating continued losses.